Aldeyra Therapeutics, Inc. (ALDX)

Market Cap	314.64M
Revenue (ttm)	n/a
Net Income (ttm)	-50.62M
Shares Out	60.05M
EPS (ttm)	-0.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	309,178
Open	5.25
Previous Close	5.18
Day's Range	5.18 - 5.29
52-Week Range	1.14 - 7.20
Beta	0.82
Analysts	Strong Buy
Price Target	9.50 (+81.3%)
Earnings Date	Nov 6, 2025

About ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 2, 2014
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: ALDX
• Website: https://www.aldeyra.com

Analyst Summary

According to 2 analysts, the average rating for ALDX stock is "Strong Buy." The 12-month stock price target is $9.5, which is an increase of 81.30% from the latest price.

Price Target

$9.5

(81.30% upside)

Analyst Consensus: Strong Buy